ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Terminated

Conditions: Lymphoma
Solid Neoplasm

Interventions: Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Ribociclib

First Posted Date: 2015-04-13

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT02414724

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Carcinoid Tumor
Metastatic Carcinoid Tumor
Neuroendocrine Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Nintedanib
Other: Pharmacological Study
Other: Quality-of-Life Assessment

First Posted Date: 2015-03-26

Last Posted Date: 2023-12-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 32

Registration Number: NCT02399215

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Rectal Adenocarcinoma
Recurrent Colon Carcinoma
Recurrent Rectal Carcinoma
Stage IVA Rectal Cancer
Stage IVA Colon Cancer
Stage IVB Rectal Cancer
Colon Adenocarcinoma
Stage IVB Colon Cancer

Interventions: Drug: Capecitabine
Other: Laboratory Biomarker Analysis
Drug: Nintedanib
Other: Pharmacological Study

First Posted Date: 2015-03-19

Last Posted Date: 2021-07-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 42

Registration Number: NCT02393755

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Phase 1

Active, not recruiting

Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell Myeloma

Interventions: Biological: Incomplete Freund's Adjuvant
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine

First Posted Date: 2015-01-08

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT02334865

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

Phase 2

Withdrawn

Conditions: Stage IIB Rectal Cancer
Rectal Adenocarcinoma
Stage IIA Rectal Cancer
Stage IIC Rectal Cancer
Stage IIIA Rectal Cancer
Stage IIIB Rectal Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Regorafenib

First Posted Date: 2014-11-11

Last Posted Date: 2016-10-12

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02287727

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Rochester Medical Center - Wilmont Cancer Institute, Rocherster, New York, United States

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Stage IV Pancreatic Cancer
Advanced Malignant Solid Neoplasm
Metastatic Pancreatic Adenocarcinoma
ALK Positive
Stage III Pancreatic Cancer

Interventions: Drug: Ceritinib
Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation

First Posted Date: 2014-08-28

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT02227940

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer

Not Applicable

Terminated

Conditions: Stage II Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage I Renal Cell Cancer

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Nephrectomy
Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003

First Posted Date: 2014-06-23

Last Posted Date: 2020-07-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02170389

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Other: Laboratory Biomarker Analysis
Drug: Epacadostat
Other: Pharmacological Study
Drug: Poly ICLC

First Posted Date: 2014-06-18

Last Posted Date: 2023-02-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02166905

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Prostate Carcinoma
Hormone-Resistant Prostate Cancer
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: Sipuleucel-T
Drug: Tasquinimod

First Posted Date: 2014-06-10

Last Posted Date: 2023-04-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02159950

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity

Phase 2

Withdrawn

Conditions: Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage I Verrucous Carcinoma of the Oral Cavity
Stage II Verrucous Carcinoma of the Oral Cavity
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Verrucous Carcinoma of the Oral Cavity
Stage IVA Verrucous Carcinoma of the Oral Cavity
Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Procedure: therapeutic conventional surgery
Drug: HPPH
Device: Light Infusion Therapy™

First Posted Date: 2014-04-22

Last Posted Date: 2016-04-21

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02119728

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy